KORU Medical Systems, Inc.: directors' dealings · United States · SEC (Form 4)

About KORU Medical Systems, Inc.

KORU Medical Systems, Inc. (ticker: KRMD) is a U.S.-based medical device company listed on the NASDAQ in the United States. For French-speaking investors, it fits the profile of a niche medtech focused on large-volume subcutaneous infusion solutions rather than pharmaceuticals. The company was incorporated in 1980 and is headquartered in Mahwah, New Jersey. Its business model is centered on a specialized segment of healthcare delivery where ease of use, reliability, and patient convenience are key differentiators. ([stockanalysis.com](https://stockanalysis.com/stocks/krmd/company/?utm_source=openai)) KORU Medical develops, manufactures, and commercializes patient-centric infusion systems used to administer therapies subcutaneously, including in the home and in ambulatory care settings. Its flagship platform is the Freedom System, which first received FDA clearance in 1994. The company also highlights FreedomEDGE, a syringe/infusion system designed for subcutaneous administration in home care, infusion centers, and other medical environments. In practical terms, KORU serves therapy areas that require repeated or specialized delivery of treatments, with an emphasis on portability, convenience, and patient experience. ([investors.korumedical.com](https://investors.korumedical.com/news-events/press-releases/detail/192/koru-medical-systems-reports-preliminary-q4-and-full-year-2025-results-achieves-record-revenue-and-full-year-positive-operating-cash-flow?utm_source=openai)) From a competitive standpoint, KORU operates in a focused niche where its long-standing technical know-how and installed base matter, but where it remains much smaller than the global medtech giants. Its competitive edge comes from specialization, application expertise, and the ability to partner with pharmaceutical and care-delivery organizations. Recent company communications suggest improving commercial momentum: in 2025, KORU reported revenue growth, improved adjusted operating profitability, and positive operating cash flow for fiscal 2025, while also raising revenue guidance. The company also announced a next-generation subcutaneous immunoglobulin infusion agreement in 2025 and presented clinical data in Europe, indicating both product development and broader geographic outreach. ([investors.korumedical.com](https://investors.korumedical.com/news-events/press-releases/detail/195/koru-medical-systems-announces-20-fourth-quarter-and-full-year-2025-revenue-growth-positive-adjusted-ebitda-and-initiates-full-year-2026-guidance?utm_source=openai)) Geographically, KORU remains primarily U.S.-anchored, but recent filings and disclosures show meaningful international activity and contribution to growth. For investors in France, Belgium, and Switzerland, KRMD should therefore be viewed as a U.S.-listed NASDAQ small-cap healthcare name with exposure to specialty medical devices, home infusion adoption, and the growing use of subcutaneous delivery pathways. The investment case is best understood as a specialized growth story, driven by execution, clinical and commercial partnerships, and expanding use cases rather than broad diversification across healthcare. ([investors.korumedical.com](https://investors.korumedical.com/sec-filings/all-sec-filings/content/0001161697-26-000107/0001161697-26-000107.pdf?utm_source=openai))